SEC Form 4 
FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 	  
OMB APPROVAL
OMB Number:	3235-0287	
Estimated average burden	
hours per response:	0.5	

	
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			
1. Name and Address of Reporting Person*
Blaser Brian J	

(Last)	(First)	(Middle)	
100 ABBOTT PARK ROAD	

(Street) 
ABBOTT PARK	IL	60064-6400	

(City)	(State)	(Zip)	
	2. Issuer Name and Ticker or Trading Symbol 
ABBOTT LABORATORIES [ ABT ] 	5. Relationship of Reporting Person(s) to Issuer 
(Check all applicable) 
	Director		10% Owner	
X	Officer (give title below)		Other (specify below)	
Executive Vice President 	
		
	3. Date of Earliest Transaction (Month/Day/Year)
02/22/2019 		
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) 
X	Form filed by One Reporting Person	
	Form filed by More than One Reporting Person	
	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned	
1. Title of Security (Instr. 3) 	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8) 	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 	7. Nature of Indirect Beneficial Ownership (Instr. 4) 	
			Code	V	Amount	(A) or (D)	Price				
Common shares without par value	02/22/2019		A		28,405(1) 	A	$00 	161,563	D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities) 	
1. Title of Derivative Security (Instr. 3) 	2. Conversion or Exercise Price of Derivative Security 	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) 	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 	8. Price of Derivative Security (Instr. 5) 	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 	11. Nature of Indirect Beneficial Ownership (Instr. 4) 	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Option (right to buy)(2) 	$75.9 	02/22/2019		A		148,895		02/22/2020	02/21/2029	Common shares	148,895	$0 	148,895	D		
Explanation of Responses:	
1. These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.	
2. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 49,631 on February 22, 2020, 49,632 on February 22, 2021, and 49,632 on February 22, 2022.	
	Jessica H. Paik, by power of attorney for Brian J. Blaser	02/26/2019	
	** Signature of Reporting Person	Date	
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.	
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).	
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).	
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.	
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.	
Exhibit 24.1

POWER OF ATTORNEY

The undersigned constitutes and appoints HUBERT L. ALLEN, JESSICA
H. PAIK, and AARON N. RICE, and each of them individually, as the
undersigned's true and lawful attorney-in-fact and agent, with
full power of substitution and re-substitution, for the
undersigned and in the undersigned's name, place and stead,
to prepare and sign any and all Securities and Exchange Commission
("SEC") Notices of Proposed Sales of Securities pursuant to Rule 144
under the Securities Act of 1933 on Form 144, all SEC statements
on Forms 3, 4 and 5 as required under Section 16(a) of the Securities
Exchange Act of 1934, including a Form ID and any other documents
necessary to obtain codes and passwords necessary to make electronic
filings, and any amendments to such forms, and to file the same with
all exhibits thereto, and other documents in connection therewith,
with the SEC, granting unto said attorney-in-fact and agent full
power and authority to do and perform each act and thing requisite,
necessary or desirable to be done under said Rule 144 and Section
16(a), as fully for all intents and purposes as the undersigned
might or could do in person, hereby ratifying and confirming all
that said attorney-in-fact and agent may lawfully do or cause to be
done by virtue hereof.

A copy of this power of attorney shall be filed with the SEC.  The
authorization set forth above shall continue in full force and effect
until the undersigned is no longer required to file Forms 144, 3, 4, or
5 or if earlier, until the undersigned revokes such authorization by
written instructions to the attorney-in-fact.

Date:  December 14, 2018

/s/ Brian J. Blaser
Signature of Reporting Person

Brian J. Blaser

Abbott Laboratories
100 Abbott Park Road
Abbott Park, IL 60064